# SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
Canonical URL: https://biopharmsignal.com/news/SLS/sellas-life-sciences-reports-first-quarter-2026-financial-results-and-provides-corporate-update
Ticker: SLS
Company: SELLAS Life Sciences Group, Inc.
Source: SELLAS Life Sciences Group, Inc.
Published: 2026-05-12 20:05 EST
Original Source URL: https://ir.sellaslifesciences.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-05-14 12:00 EST — [SELLAS Life Sciences to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/SLS/sellas-life-sciences-to-participate-in-upcoming-investor-conferences) — Source: SELLAS Life Sciences Group, Inc.
- 2026-05-12 20:05 EST — [SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/SLS/sellas-life-sciences-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: SELLAS Life Sciences Group, Inc.
- 2026-03-19 20:05 EST — [SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/SLS/sellas-life-sciences-reports-full-year-2025-financial-results-and-provides-corporate-update) — Source: SELLAS Life Sciences Group, Inc.
- 2026-03-17 20:30 EST — [SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference](https://biopharmsignal.com/news/SLS/sellas-life-sciences-to-present-preclinical-data-highlighting-potent-activity-of-sls009-in-aml-at-the-2026-aacr-conference) — Source: SELLAS Life Sciences Group, Inc.
- 2026-03-12 12:35 EST — [SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009](https://biopharmsignal.com/news/SLS/sellas-life-sciences-announces-enrollment-of-first-patient-in-newly-diagnosed-first-line-aml-trial-of-sls009) — Source: SELLAS Life Sciences Group, Inc.
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)